

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	09780035
		Filing Date	2001-02-09
		First Named Inventor	Tariq Ghayur
		Art Unit	1644
		Examiner Name	Gambel, Phillip
Sheet	of	Attorney Docket Number	BBC-084/US

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	51	MCINNES, IAIN B. et al., Interleukin 18: a pleiotropic participant in chronic inflammation, Immunology Today (2000) Vol. 21, pgs. 312-315		
	52	MENDEZ, MICHAEL J. et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics (1997), Vol. 15, 146-156		
	53	MIZUSHIMA, SEIICHI et al., pEF-BOS, a powerful mammalian expression vector, Nucleic Acids Research, (1990) Vol. 18(17), pg. 5322		
	54	MONTELEONE, GIOVANNI et al., Bioactive IL-18 Expression is up-Regulated in Chron's Disease, Journal of Immunology, (1999) Vol. 163(1), pgs. 143-147		
	55	NETEA, MIHAI G. et al., Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation, The Journal of Immunology (2000) Vol. 164, pgs. 2644-2649		
	56	POLJAK, ROBERTO J., Production and Structure of diabodies, Structure (1994), Vol. 2, pgs. 1121-1123		
	57	QUEEN, CARY et al., A human antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci., (1989) Vol. 86, pgs. 10029-10033		
	58	REICHMANN, LUTZ et al., Reshaping human antibodies for therapy, Nature (1988), Vol. 332, pgs. 323-327		
	59	TAKEDA, KIYOSHI et al., Defective Nk Cell Activity and Th1 Response in IL-18 Deficient Mice, Immunity (1998) Vol. 8, pgs. 383-390		
	60	TANIGUCHI, MUTSUO et al., Characterization of anti-human interleukin-18 (IL-18), Journal of Immun. Methods (1997) Vol. 206; 107-113		

Examiner Signature	/Phillip Gambel/ 	Date Considered	12/21/2009	05/18/2009
--------------------	--	-----------------	------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	09780035		
		Filing Date	2001-02-09		
		First Named Inventor	Tariq Ghayur		
		Art Unit	1644		
		Examiner Name	Gambel, Phillip		
Sheet	of		Attorney Docket Number	BBC-084/US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	61	TAYLOR, LISA D. et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immun, Nucleic Acids Research (1992), Vol. 20(23), pgs. 6287-6295		
	62	TISSI, LUCIANA et al., Role of Tumor Necrosis Factor Alpha, Interleukin-1B and Interleukin-6 in a mouse model of Group B, Infection and Immunity (1999), Vol. 67, 4545-4550		
	63	TRENTHAM, DAVID E. et al., Autoimmunity to Type II Collage: An Experimental Model of Arthritis, Journal of Exp. Med. (1977) Vol. 146, pgs. 857-868		
	64	TSUTSUI, HIROKO et al, Caspase-1 Independent, Fas/Fas/ Ligand-Mediated IL-18 Secretion from Macrophages Cases Acute liver injury in Mice, Immunity (1999) Vol. 11, pgs. 359-367		
	65	TSUTSUI, HIROKO et al., IL-18 Accounts for both TNF-a- and Fas Ligand-Mediated Hpatotoxic Pathways, Jour. of Immun., (1997), Vol. 159(8) pgs. 3961-3967		
	66	URLAUB GAIL et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Pro. Natl. Acad. Sci. (1980) Vol. 77(7), pgs. 4216-4220		
	67	USHIO SHIMPEI et al., Cloning of the cDNA for Human IFN- $\gamma$ -Inducing Factor, Expression in Escherichia coli, Journal of Immunology (1996) Vol. 156, pgs. 4274-4279		
	68	VAN NOSTRAND, WILLIAM E. et al., Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid B-protein precursor, Nature (1989) Vol. 341, pgs. 546-551		
	69	WILDBAUM, GIZI et al., Neutralizing Antibodies to IF- $\gamma$ -inducing Factor Prevent Experimental Autoimmune Encaphalomyelitis, Journ. of Immun. (1998) Vol. 161(11), pgs. 6368-6374		
	70	WINTER, GREG et al., Making Antibodies by Phage Display Technology, Annua. Rev. of Immun. (1994), Vol. 12, pgs. 433-455		

Examiner Signature	/Phillip Gambel/ 	Date Considered	12/21/2009
--------------------	--	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./